Critical Outcome Technologies and Delmar Chemicals Sign Collaboration Agreement
News Sep 12, 2012
Critical Outcome Technologies Inc. and Delmar Chemicals Inc., a Canadian company owned by Holding F.I.S S.p.A announced that they have entered into a research and development collaboration agreement to advance selected small molecules. COTI and Delmar will work together to discover, select, screen and synthesize compounds for targets that have been identified as being of specific interest to major pharmaceutical companies.
Under the agreement, COTI will utilize its proprietary Artificial Intelligence drug discovery platform, CHEMSAS®, to discover and optimize novel drug candidates designed to effectively address a number of highly desirable commercial and therapeutic opportunities. Delmar will take on the medicinal chemistry analysis of the chemical structures as well as the synthesis of the most promising candidates. Strategically, the collaboration leverages the unique technical capabilities and financial resources of both COTI and Delmar in developing patentable preclinical assets for outlicensing.
"We are excited to work with Delmar, a recognized industry leader in medicinal chemistry, to generate additional patentable products for our mutual benefit," said Dr. Wayne Danter, President and Chief Executive Officer of COTI. "This collaboration represents an opportunity to extend the intellectual property in COTI's growing portfolio and assists in positioning CHEMSAS®' as a potential drug discovery engine of choice in the biopharmaceutical and research community."
According to Pierre Plante, President & CEO of Delmar, "We have great confidence in CHEMSAS® and are pleased to be collaborating with COTI on this project. Synthesizing the molecules identified by COTI provides us with a unique opportunity to demonstrate our expertise in medicinal chemistry."
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Researchers Test Drug Transfer Using Placenta-On-A-ChipNews
Researchers have demonstrated the feasibility of their "organ-on-a-chip" platform in studying how drugs are transported across the human placental barrier.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018